Foreign Corrupt Practices Act Raises Disclosure Dilemma For Internal Investigations
This article was originally published in PharmAsia News
Executive Summary
While companies are feeling pressure to voluntarily disclose potential violations of the U.S. Foreign Corrupt Practices Act, it may not always be the most prudent action, former government attorneys suggested at a recent meeting
You may also be interested in...
Attorney Richard Cassin On FCPA’s Impact On Foreign Acquisitions And Competitor Snitching: An Interview With PharmAsia News
Pharmaceutical companies face stepped up scrutiny of acquisitions and the possibility that competitors will point fingers at suspected fraud in order to lessen their own enforcement actions and penalties.
Attorney Richard Cassin On FCPA’s Impact On Foreign Acquisitions And Competitor Snitching: An Interview With PharmAsia News
Pharmaceutical companies face stepped up scrutiny of acquisitions and the possibility that competitors will point fingers at suspected fraud in order to lessen their own enforcement actions and penalties.
Corruption Laws Take Front Seat In Asian Deal Making Decisions And Expansion Plans
Multinational firms in Asia need to consider building independent in-house compliance teams to guard against mistakes in handling corruption cases, compliance and risk management, experts advise.